Patents by Inventor Ute Egerland

Ute Egerland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Triazoles as NR2B receptor inhibitors
    Patent number: 10323021
    Abstract: Provided here in are compounds of Formula I having the structure: Also provided herein are compositions comprising compounds of Formula I and methods of using compounds of Formula I for the treatment of disorders, diseases or conditions mediated by GluN2B receptors.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: June 18, 2019
    Assignee: JANSSEN PHARMACEUTICALS, INC.
    Inventors: Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Ute Egerland, Barbara Langen, Rita Dost, Simon Ward
  • Pyrazoles
    Patent number: 10155727
    Abstract: The invention relates to pyrazole derivatives which are NMDA NR2B receptor inhibitors, useful in treating central nervous system diseases.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: December 18, 2018
    Assignee: JANSSEN PHARMACEUTICALS, INC.
    Inventors: Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Christian Grunwald, Ute Egerland, Barbara Langen, Rita Dost, Thorsten Hage, Simon Ward
  • TRIAZOLES AS NR2B RECEPTOR INHIBITORS
    Publication number: 20180282305
    Abstract: Provided here in are compounds of Formula I having the structure: Also provided herein are compositions comprising compounds of Formula I and methods of using compounds of Formula I for the treatment of disorders, diseases or conditions mediated by GluN2B receptors.
    Type: Application
    Filed: April 27, 2018
    Publication date: October 4, 2018
    Inventors: Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Ute Egerland, Barbara Langen, Rita Dost, Simon Ward
  • Triazoles as NR2B receptor inhibitors
    Patent number: 9981950
    Abstract: Provided here in are compounds of Formula I having the structure: Also provided herein are compositions comprising compounds of Formula I and methods of using compounds of Formula I for the treatment of disorders, diseases or conditions mediated by GluN2B receptors.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: May 29, 2018
    Assignee: JANSSEN PHARMACEUTICALS, INC.
    Inventors: Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Ute Egerland, Barbara Langen, Rita Dost, Simon Ward
  • PYRAZOLES
    Publication number: 20170275254
    Abstract: The invention relates to pyrazole derivatives which are NMDA NR2B receptor inhibitors, useful in treating central nervous system diseases.
    Type: Application
    Filed: August 14, 2015
    Publication date: September 28, 2017
    Inventors: Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Christian Grunwald, Ute Egerland, Barbara Langen, Rita Dost, Thorsten Hage, Simon Ward
  • TRIAZOLES AS NR2B RECEPTOR INHIBITORS
    Publication number: 20170226087
    Abstract: Provided here in are compounds of Formula I having the structure: Also provided herein are compositions comprising compounds of Formula I and methods of using compounds of Formula I for the treatment of disorders, diseases or conditions mediated by GluN2B receptors.
    Type: Application
    Filed: August 14, 2015
    Publication date: August 10, 2017
    Inventors: Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Ute Egerland, Barbara Langen, Rita Dost, Simon Ward
  • Substituted pyrido[3,2-E][1,2,4]-triazolo[4,3-A]pyrazines for the treatment of central nervous system disorders
    Patent number: 9085584
    Abstract: The compounds are of the class of pyrido[3,2-e][1,2,4]-tiazolo[4,3-a]pyrazines, useful in the treatment of central nervous system disorders.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: July 21, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Riccardo Giovannini, Barbara Bertani, Sara Frattini, Giustino Di Antonio, Hans-Joachim Lankau, Hans Stange, Christian Grunwald, Norbert Höfgen, Barbara Langen, Ute Egerland
  • 7-azaindoles and the use thereof as therapeutic agents
    Patent number: 7947705
    Abstract: The invention relates to substituted 7-azaindoles, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: May 24, 2011
    Assignee: Biotie Therapies GmbH
    Inventors: Norbert Höfgen, Hildegard Kuss, Matthias Olbrich, Ute Egerland, Chris Rundfeldt, Karin Steinike, Rudolf Schindler
  • Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders
    Patent number: 7875618
    Abstract: The invention relates to imidazo[1,5-a]quinoxaline derivatives having Formula IIa: to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10 (PDE10), as active compounds for treating central nervous system diseases of mammals, including humans.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: January 25, 2011
    Assignees: Wyeth, elbion GmbH
    Inventors: Michael S. Malamas, Yike Ni, James Joseph Erdei, Norbert Höfgen, Hans Stange, Rudolf Schindler, Ute Egerland, Barbara Langen
  • IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES
    Publication number: 20100120763
    Abstract: The invention relates to imidazo[5,1-c][1,2,4]benzotriazine derivatives of formula I: which are inhibitors of phosphodiesterase 2 or 10 useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type 2 diabetes, metabolic syndrome, glucose intolerance, and pain.
    Type: Application
    Filed: November 6, 2009
    Publication date: May 13, 2010
    Applicant: WYETH
    Inventors: Hans Stange, Barbara Langen, Ute Egerland, Norbert Hoefgen, Martina Priebs, Michael S. Malamas, James Joseph Erdei, Yike Ni
  • Triazine derivatives as inhibitors of phosphodiesterases
    Publication number: 20100120762
    Abstract: The invention relates to triazine derivatives of formula (I): which are inhibitors of phosphodiesterase 2 or 10, useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type 2 diabetes, metabolic syndrome, glucose intolerance, and pain.
    Type: Application
    Filed: November 6, 2009
    Publication date: May 13, 2010
    Applicant: WYETH
    Inventors: Hans Stange, Barbara Langen, Ute Egerland, Norbert Hoefgen, Martina Priebs, Michael S. Malamas, James Joseph Erdei, Yike Ni
  • 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them
    Patent number: 7683074
    Abstract: 7-azaindoles inhibit phosphodiesterase 4 (PDE4). Methods for preparing these compounds and methods of treating arthritis and other conditions with the compounds are also provided.
    Type: Grant
    Filed: March 10, 2008
    Date of Patent: March 23, 2010
    Assignee: Biotie Therapies GmbH
    Inventors: Norbert Höfgen, Ute Egerland, Thomas Kronbach, Degenhard Marx, Stefan Szelenyi, Hildegard Kuss, Emmanuel Polymeropoulos
  • Pyrido[3,2-e]pyrazines, their use as inhibitors of phospohodiesterase 10, and processes for preparing them
    Publication number: 20090239874
    Abstract: The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating diseases of mammals including a human which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 10 activity in the central nervous system. More particularly, the invention relates to the treatment of neurologic and psychiatric disorders, for example psychosis and disorders comprising cognitive deficits as symptoms.
    Type: Application
    Filed: May 19, 2009
    Publication date: September 24, 2009
    Inventors: Norbert Hofgen, Hans Stange, Barbara Langen, Ute Egerland, Rudolf Schindler, Thomas Pfeifer, Chris Rundfeldt
  • Pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
    Patent number: 7550465
    Abstract: The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating diseases of mammals including a human which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 10 activity in the central nervous system. More particularly, the invention relates to the treatment of neurologic and psychiatric disorders, for example psychosis and disorders comprising cognitive deficits as symptoms.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: June 23, 2009
    Assignee: Elbion GmbH
    Inventors: Norbert Höfgen, Hans Stange, Barbara Langen, Ute Egerland, Rudolf Schindler, Thomas Pfeifer, Chris Rundfeldt
  • Methods of Treating Obesity and Metabolic Disorders
    Publication number: 20090143392
    Abstract: The invention relates to methods of treating or preventing obesity, type 2 diabetes, metabolic syndrome, or glucose intolerance using pyrido[3,2-e]pyrazines which are inhibitors of PDE10. The invention further relates to methods of reducing body fat or body weight.
    Type: Application
    Filed: November 25, 2008
    Publication date: June 4, 2009
    Applicant: ELBION GMBH
    Inventors: Norbert Hofgen, Hans Stange, Barbara Langen, Ute Egerland, Rudolf Schindler, Antje Gasparic, Chris Rundfeldt, Thomas Pfeifer
  • ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10
    Publication number: 20090143367
    Abstract: The invention relates to imidazo[1,5-a]pyrazine derivatives, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10 (PDE10), as active compounds for treating central nervous system diseases of mammals, including humans.
    Type: Application
    Filed: November 25, 2008
    Publication date: June 4, 2009
    Applicants: ELBION GMBH, WYETH
    Inventors: Michael S. Malamas, Yike Ni, James Joseph Erdei, Norbert Hofgen, Hans Stange, Rudolf Schindler, Ute Egerland, Barbara Langen
  • Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
    Publication number: 20090143361
    Abstract: The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical compositions which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating central nervous system disorders, obesity, and metabolic disorders.
    Type: Application
    Filed: November 25, 2008
    Publication date: June 4, 2009
    Applicants: ELBION GMBH, WYETH
    Inventors: Michael S. Malamas, Yike Ni, James Joseph Erdei, Hans Stange, Rudolf Schindler, Norbert Hofgen, Ute Egerland, Barbara Langen
  • Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10
    Publication number: 20090143391
    Abstract: The invention relates to imidazo[1,5-a]pyrazine derivatives, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10 (PDE10), as active compounds for treating central nervous system diseases of mammals, including humans.
    Type: Application
    Filed: December 1, 2008
    Publication date: June 4, 2009
    Inventors: Norbert Hofgen, Hans Stange, Barbara Langen, Ute Egerland, Rudolf Schindler
  • 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them
    Patent number: 7419987
    Abstract: 7-azaindoles inhibit phosphodiesterase 4 (PDE4). Methods for preparing these compounds are also provided.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: September 2, 2008
    Assignee: Elbion AG
    Inventors: Norbert Höfgen, Ute Egerland, Thomas Kronbach, Degenhard Marx, Stefan Szelenyi, Hildegard Kuss, Emmanuel Polymeropoulos
  • Pyrazoles
    Patent number: RE49517
    Abstract: The invention relates to pyrazole derivatives which are NMDA NR2B receptor inhibitors, useful in treating central nervous system diseases.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: May 2, 2023
    Assignee: JANSSEN PHARMACEUTICALS, INC.
    Inventors: Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Christian Grunwald, Ute Egerland, Barbara Langen, Rita Dost, Thorsten Hage, Simon Ward